Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced that the first patient was enrolled and treated in its CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial
News | Cardiovascular Clinical Studies
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

December 19, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home December 19, 2023
Home
Smidt Heart Institute investigators develop algorithm that uses electrocardiograms to risk-stratify patients, prescribe appropriate treatment
News | Artificial Intelligence
New Artificial Intelligence Tool Predicts Mortality After Heart Surgeries

December 18, 2023 — An artificial intelligence (AI) tool developed by investigators at  the Smidt Heart Institute at ...

Home December 18, 2023
Home
Rating measures quality, safety, and outcomes of the five most common heart procedures
News | Cardiovascular Surgery
Cardiovascular Surgery at the Mount Sinai Hospital Wins Highest Quality National Ratings from Society of Thoracic Surgeons

December 18, 2023 — The Department of Cardiovascular Surgery at The Mount Sinai Hospital has received the highest ...

Home December 18, 2023
Home
Henry Ford Health's National Cardiogenic Shock Initiative research team.
News | Cardiovascular Clinical Studies
National Cardiogenic Shock Initiative Study Results Show Significant Increase in Heart Attack Survival

December 14, 2023 — Published results of a large, national heart attack study show that patients with a life-threatening ...

Home December 14, 2023
Home
Early detection of atrial fibrillation can reduce the risk of stroke and heart failure, but screening people for the condition has been historically challenging
News | Atrial Fibrillation
New AI-powered Algorithm Could Better Assess People’s Risk of Common Heart Condition

December 13, 2023 — A new artificial intelligence (AI) model designed by Scripps Research scientists could help ...

Home December 13, 2023
Home
University of Virginia School of Medicine researchers have created an “atlas of atherosclerosis” that reveals, at the level of individual cells, critical processes responsible for forming the harmful plaque buildup that causes heart attacks, strokes and coronary artery disease. 
News | Stroke
New 'Atherosclerosis Atlas' Sheds Light on Heart Attacks, Strokes

December 13, 2023 — University of Virginia School of Medicine researchers have created an “atlas of atherosclerosis” ...

Home December 13, 2023
Home
UC Gardner Neuroscience Institute
News | Stroke
UC Gardner Neuroscience Institute to Lead New National Stroke Study

December 8, 2023 — Ischemic stroke is the most common form of stroke in the U.S., affecting more than 690,000 people ...

Home December 08, 2023
Home
The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy.
News | Cardiovascular Clinical Studies
Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix Percutaneous Mechanical Circulatory Support Technology

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
Raymond Benza, MD, Chief of Pulmonary Hypertension for the Mount Sinai Health System
News | Cardiovascular Business
Raymond Benza, MD, Heart Failure Expert, Named Chief of Pulmonary Hypertension for the Mount Sinai Health System

December 5, 2023 — Raymond Benza, MD, FACC, FAHA, FACP, a top expert in cardiovascular medicine and advanced heart ...

Home December 05, 2023
Home
Japan’s PMDA asked for further details on a number of elements included in BioCardia’s CardiAMP preclinical and clinical packages in order to gain approval.
News | Heart Failure
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

November 30, 2023 —  BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiov ...

Home November 30, 2023
Home
Data from all three patients in non-randomized cohort treated with DSR 2.0 indicate safe and effective maintenance of euvolemia without the need for loop diuretics, considerable benefit in cardiorenal status and dramatic improvement in diuretic response and loop diuretic requirements up to 11 weeks post DSR treatment
News | Heart Failure
Sequana Medical Announces Positive Data from Non-randomized Cohort in US Phase 1/2a MOJAVE Study of DSR 2.0 for Treatment of Heart Failure

November 30, 2023 —  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure an ...

Home November 30, 2023
Home
Impella Improves Survival and Heart Recovery
News | Cardiovascular Clinical Studies
First Patient Enrolled in Abiomed’s RECOVER IV Randomized Controlled Trial of Impella as a Therapy for AMI Cardiogenic Shock

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)
News | FDA
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

November 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home November 27, 2023
Home
The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient.
News | Cardiovascular Clinical Studies
Trial to Prevent Sudden Death After a Heart Attack Enrolls First Patient

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial ...

Home November 22, 2023
Home
New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots
News | Heart Valve Technology
Late-breaking Data Show an Aspirin-free Medication Regimen Benefits People with Abbott’s HeartMate 3 Heart Pump

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its He ...

Home November 20, 2023
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now